Richiedi info sul prodotto
Estimated delivery: 1-3 business days
Information on returns and shipments
Payment methods
Anti-inflammatory patches.
Dolaut Mono is indicated for the treatment of painful and inflammatory conditions of a rheumatic and traumatic nature of the joints, muscles, tendons and ligaments.
One patch measuring 100 x 70 mm (70 cm²) contains 14 mg of piroxicam. For the full list of excipients, see section 6.1.
Acrylic copolymer, Eudragit E 100; non-woven fabric, siliconized polyester.
Hypersensitivity to the active substance (piroxicam) or to any of the excipients. Patients in whom substances with a similar mechanism of action (NSAIDs) have caused hypersensitivity reactions (see section 4.4). DOLAUT MONO is contraindicated in patients with active peptic ulcer, patients with bronchial asthma, a history of gastrointestinal bleeding from NSAIDs. Patients on anticoagulant therapy. Pregnancy and breastfeeding (see section 4.6). Children under 12 years of age. DOLAUT MONO 14 mg medicated plaster should not be used on open wounds or lesions, but only on intact skin. Avoid contact with eyes and mucous membranes.
It is recommended to use only one medicated plaster at a time and replace it every 24 hours for a period not exceeding 8 days. Do not apply two plasters on the same day. DOLAUT MONO is for use only on intact skin. After carefully washing and drying the painful area, rub one of the corners of DOLAUT MONO between your fingers to remove the protective film and apply the adhesive side directly to the skin. If DOLAUT MONO needs to be applied to more mobile joints, such as the elbow or knee, it is advisable to use a retention bandage to apply to the flexed joint to keep the patch in place. Do not exceed the recommended doses.
This medicine does not require any special storage conditions.
The serum levels achieved with DOLAUT MONO were significantly lower than those obtained through oral administration, but with strong individual variability, so the onset of systemic side effects, especially at the gastrointestinal level, cannot be ruled out. Analgesics, antipyretics, and nonsteroidal anti-inflammatory drugs, including piroxicam, can cause hypersensitivity reactions, potentially serious even in subjects not previously exposed to this type of drug. These include asthma attacks, skin rashes, allergic rhinitis, and anaphylactic-type reactions. DOLAUT MONO should be used with caution in subjects with chronic obstructive bronchial disease, allergic rhinitis, or inflammation of the nasal mucosa (nasal polyps), in whom asthma attacks or localized inflammatory reactions of the skin and mucosa (Quincke's edema) are more frequent. Use caution in patients with a history of peptic ulcer, in patients with a history of gastrointestinal bleeding not secondary to the administration of NSAIDs or with other bleeding disorders, in patients with Crohn's disease or ulcerative colitis, with severe liver or kidney dysfunction, or with heart failure. Prolonged or repeated use of products for skin application may cause allergic reactions. give rise to sensitization phenomena. If hypersensitivity reactions occur, discontinue therapy. Caution should be exercised when treating elderly patients, who are generally more prone to adverse events. After a short period of therapy without results, consult your doctor. To avoid possible hypersensitivity or photosensitivity phenomena, avoid exposure to direct sunlight. Keep the medicine out of the reach and sight of children.
The use of piroxicam-based patches is unlikely to cause interactions with other medicinal products. However, the possibility of competition between absorbed piroxicam and other drugs highly bound to plasma proteins cannot be ruled out. Do not use the product together with other oral or local medications containing piroxicam or other NSAIDs.
The use of the product may cause serious side effects. cause local skin reactions of an irritant or allergic nature such as erythema, itching, burning, contact dermatitis, numbness and tingling at the application site; cases of extensive and severe dermatological lesions such as urticaria, Quincke's edema, and erythema multiforme have been reported with this type of medicine. Photosensitivity reactions and more extensive and more severe skin and mucosal reactions, including asthma attacks, are possible. Systemic adverse reactions following topical use of piroxicam are unlikely; since the plasma levels obtained are lower than those measured after systemic administration but vary greatly from individual to individual, it is not possible to exclude, especially in the case of prolonged therapy beyond the recommended term and non-compliance with contraindications and warnings, the appearance of systemic adverse effects, especially at the gastrointestinal level (see sections 4.4 and 5.2). Any general or site-specific side effects require discontinuation of therapy.
There are no known cases of overdose. In case of overdose with evident clinical manifestations, immediately initiate symptomatic therapy and apply the usual emergency measures.
DOLAUT MONO is contraindicated during pregnancy and breastfeeding and is not recommended in women intending to become pregnant. Administration should be suspended in women with fertility problems or who are undergoing fertility investigations.
Pack of 8 medical patches
This product has been on sale since 25/09/2017
In the last 30 days, the product's lowest price was 16,6 €
Ottimo prodotto
Estimated delivery: 1-3 business days
Estimated delivery: 1-3 business days
Estimated delivery: 1-3 business days
Estimated delivery: 1-3 business days
